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Abstract
Background: Adalimumab, a biological treatment targeting tumour necrosis factor α, might be useful in sciatica.
This paper describes the challenges faced when developing a new treatment pathway for a randomised controlled
trial of adalimumab for people with sciatica, as well as the reasons why the trial discussed was stopped early.
Methods: A pragmatic, parallel group, randomised controlled trial with blinded (masked) participants, clinicians,
outcome assessment and statistical analysis was conducted in six UK sites. Participants were identified and recruited
from general practices, musculoskeletal services and outpatient physiotherapy clinics. They were adults with persistent
symptoms of sciatica of 1 to 6 months’ duration with moderate to high level of disability. Eligibility was assessed by
research physiotherapists according to clinical criteria, and participants were randomised to receive two doses of
adalimumab (80 mg then 40 mg 2 weeks later) or saline placebo subcutaneous injections in the posterior lateral thigh.
Both groups were referred for a course of physiotherapy. Outcomes were measured at baseline, 6-week, 6-month and
12-month follow-up. The main outcome measure was disability measured using the Oswestry Disability Index. The
planned sample size was 332, with the first 50 in an internal pilot phase.
Results: The internal pilot phase was discontinued after 10 months from opening owing to low recruitment (two of
the six sites active, eight participants recruited). There were several challenges: contractual delays; one site did not
complete contract negotiations, and two sites signed contracts shortly before trial closure; site withdrawal owing to
patient safety concerns; difficulties obtaining excess treatment costs; and in the two sites that did recruit, recruitment
was slower than planned because of operational issues and low uptake by potential participants.
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Conclusions: Improved patient care requires robust clinical research within contexts in which treatments can
realistically be provided. Step changes in treatment, such as the introduction of biologic treatments for severe sciatica,
raise complex issues that can delay trial initiation and retard recruitment. Additional preparatory work might be
required before testing novel treatments. A randomised controlled trial of tumour necrosis factor-α blockade is still
needed to determine its cost-effectiveness in severe sciatica.
Trial registration: Current Controlled Trials, ISRCTN14569274. Registered on 15 December 2014.
Keywords: Feasibility, Randomised controlled trial, Economic evaluation, Sciatica, Adalimumab, Anti-TNF-α, Biological
agents,
Background
Sciatica is a well-localised leg pain, attributed to nerve
root irritation, that approximates the dermatomal distri-
bution of the sciatic nerve down the posterior lateral as-
pect of the leg [1]. It is a common cause of pain and
disability [2]. Although most cases resolve, up to 30%
might have persistent troublesome symptoms after 1 year
[3, 4]. Many patients whose symptoms settle relapse later
[5]. Typical care pathways in the National Health Service
(NHS) involve analgesia prescribed by a general practi-
tioner (GP), referral for physiotherapy [6, 7], followed by
more invasive treatment, such as epidural corticosteroid
injection or disc surgery if symptoms persist [3, 4, 8].
However, the evidence for most of the non-surgical treat-
ments is weak [9]; new treatment strategies are needed.
Sciatica caused by lumbar nerve root pain usually arises
from a prolapsed intervertebral disc [3], which can
compress the nerve root [10] but also releases
pro-inflammatory factors such as tumour necrosis factor-α
(TNF-α) that may lead to nerve sensitisation [11, 12].
Biological agents such as the monoclonal antibody adalimu-
mab bind specifically to TNF-α receptors and might have
beneficial effects on the inflamed nerve root in sciatica [13].
Two separate network meta-analyses of different treatment
strategies for sciatica found that biological agents had the
highest probability of having the best outcomes for pain,
but with wide confidence intervals [14, 15]. A meta-analysis
of biological agents for sciatica found insufficient evidence
to change practice but sufficient evidence to suggest that
clinically important benefit was possible and that a defini-
tive randomised controlled trial (RCT) was warranted [16].
Sciatica is costly to society [17], and although bio-
logical agents are expensive, they may be cost-effective if
they reduce the need for more expensive treatments
such as disc surgery. Also, as patents expire, cheaper
biosimilar drugs are becoming available [18]. Adalimu-
mab is a TNF-α-blocking antibody that is administered
by subcutaneous injection, with two doses given 2 weeks
apart, and should inhibit TNF-α for at least 4 weeks.
Adalimumab dosing for psoriasis or Crohn’s disease uses
80-mg followed by 40-mg subcutaneous injections [19];
the same dosing strategy is proposed in sciatica.
Objectives
The aims of the RCT were to evaluate the effectiveness
and cost-effectiveness of injections of adalimumab plus
physiotherapy compared with placebo injection of 0.9%
sodium chloride plus physiotherapy for patients with
sciatica for whom first-line primary care treatment had
failed. However, the RCT was discontinued because of
lack of progress. The aim of this paper is to explore the
reasons for this and make recommendations to inform
other researchers.
Methods
This was designed as a pragmatic, multi-centre RCT with
blinded (masked) participants, clinicians, outcome assess-
ment and statistical analysis, with concurrent economic
evaluation and internal pilot. The Wales Research Ethics
Committee (REC) 3 granted approval on 27 May 2015 (15/
WA/105), and clinical trial authorisation from the Medi-
cines and Healthcare products Regulatory Agency (MHRA)
was granted on 15 April 2015 (21996/0002/001-0001). The
setting was the NHS in England and Wales, with five col-
laborating university centres (designated 1–5). We aimed
to recruit from six NHS sites overseen by these five centres
(designated A–F). Each collaborating centre would oversee
a number of patient identification centres, which consisted
of general medical practices, local musculoskeletal services
and outpatient physiotherapy clinics. Patients were identi-
fied in three ways:
1. By their GP
2. Following a search of the general practice patient
record database
3. After referral to local musculoskeletal services
Patients were invited to participate by letter. Those who
were interested were contacted by telephone for
pre-screening, and if they fitted the inclusion criteria, were
given an appointment in a research clinic run by a re-
search physiotherapist. At this research clinic, all potential
participants were screened by the research physiotherapist
for eligibility. If eligible, participants had blood tests,
tuberculosis (TB) screening, biological agents counselling,
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and magnetic resonance imaging (MRI) to exclude serious
spinal pathology. If they were still eligible, at a second
screening assessment 2–3 weeks later, informed consent
was obtained for trial entry and randomisation (Fig. 1).
Inclusion criteria
 Clinical features of sciatica
○ Leg pain worse than or as bad as back pain
○ Unilateral leg pain approximating a dermatomal
distribution
○ Positive neural tension test such as straight leg
raise test restricted < 50 degrees by leg pain, or
positive femoral stretch test, or muscle weakness,
or loss of tendon reflex, or loss of sensation in a
dermatomal distribution
 18 years of age or older
 Persistent symptoms for ≥ 4 weeks and < 6 months
 Moderate to high severity (≥ 30) on Oswestry
Disability Index (ODI)
Exclusion criteria
 Unable to undergo MRI
 Serious pathology
 Neurological deficit requiring urgent spinal surgery
assessment
Severe symptoms, referral for MRI and 1st consent
Failed primary care treatment or referred to local musculoskeletal service 
(>4/52, <6/12 duration, severe symptoms or recurrence), screened for 
eligibility criteria and trial information sent
Physiotherapy clinical assessment and screening 
Serious spinal pathology 
excluded
MRI findings used in planned 
sub-group analysis
Mild symptoms – advice
Discharge back to GP care
Remote 
Randomisation
Adalimumab injection 80mg then 
40mg after 2 weeks 
(sub-cutaneous) (n=166)
Concurrent physiotherapy 
intervention
Placebo injection repeated after 2 
weeks (n=166)
Concurrent physiotherapy 
intervention
MRI scan, TB screening, biological agent 
counselling, blood and urine tests
Postal outcome measures at 6 weeks 
Symptoms settled
Discharge back to GP care
Symptoms persist
Further treatment planned with MRI
Semi-structured telephone interviews at 12 months (n=266)
Postal outcome measures at 6 months 
2nd clinical assessment, 2nd consent, baseline 
outcome measurement (n=332)
Postal outcome measures at 12 months (n=266)
Telephone contact by research physiotherapist to determine potential 
eligibility. If so appointment given for research physiotherapy clinic
 
Fig. 1 Trial flowchart. GP General practitioner, MRI Magnetic resonance imaging, TB Tuberculosis
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 Contralateral leg pain extending below the inferior
gluteal margin
 Widespread pain throughout the body
 Prior use of biological agents within previous 6
months
 Previous lumbar spinal surgery
 Contraindications to adalimumab injection
 Unable to give informed consent
Randomisation
Secure web-based randomisation was performed using a
dynamic adaptive randomisation algorithm [20] to protect
against subversion while ensuring that the trial maintained
good balance to the allocation ratio of 1:1, both within
each stratification variable and across the trial. Participants
were stratified by (1) treatment centre and (2) presence of
neurological signs (motor weakness or sensory loss).
Interventions
All participants were randomised to receive an 80-mg
adalimumab subcutaneous injection followed 2 weeks
later by a 40-mg injection in the posterior thigh, or an
equivalent volume of 0.9% sodium chloride. Both groups
received a concurrent course of physiotherapy over a
period of 12 weeks [21, 22].
Internal pilot trial phase
The internal pilot trial phase aimed to assess the feasibility
of the trial procedures, recruitment and retention rates,
based on the first 50 participants recruited. The stopping
criteria at the end of this internal pilot were recruitment
which failed to reach 80% of the planned recruitment rate
target, dropouts exceeding 20%, or more than one centre
failing to commence recruitment.
Outcome measures
The baseline questionnaire was administered by research
physiotherapists. We planned to send postal question-
naires at 6 weeks, 6 months and 12 months
post-randomisation. The primary clinical outcome was
back pain-related disability using the ODI [23] measured
at 12 months, which has evidence of validity for sciatica
as well as back pain. The primary economic outcome
was quality-adjusted life-year calculated from the Euro-
Qol 5-level EQ-5D version (EQ-5D-5L) [24].
Condition-specific outcomes
 Oswestry Disability Index [23]
 Leg pain version of the Roland-Morris Disability
Questionnaire [25, 26]
 Sciatica Bothersomeness Index [27]
 Pain location using a pain manikin [28]
Generic outcomes
 EuroQol EQ-5D-5L [24]
 Global assessment of change since baseline
Psychological outcome
 Hospital Anxiety and Depression Scale [29]
Use of health care and social care services
 Resource use questionnaire [30, 31]
Process measures (potential predictors and mediators of
outcome)
 Keele STarT Back Risk Screening Tool [32]
 Pain trajectory (based on a single question) [33]
 Pain Self-Efficacy Questionnaire [34]
 Tampa Scale for Kinesiophobia [35]
Sample size
In order to detect an effect size of 0.4 with 90% power,
5% significance and 80% retention rate, 332 patients
would have needed to be recruited.
Written qualitative comments
After the trial funding was withdrawn because of slow
progress, the trial management team and all sites were
asked to reflect on what worked and what did not work
within the trial. Written comments were collated by the
trial manager (AJ) and the chief investigator (NHW) and
grouped into themes.
Results
Trial progress
Trial progress is compared with what was planned, as
shown in Fig. 2. The letter of notification of funding was
received on 11th August 2014. The trial documentation
for the regulatory approval was in place in December
2014. Regulatory approval was obtained from the MHRA
on 15th April 2015 and from the REC on 27th May
2015. There were long delays in signing contracts with
University 4 and NHS sites D and E, and contracts were
never signed with University 5 and NHS site F (Table 1).
There were delays in obtaining the excess treatment
costs (ETCs) for some sites in England. University 3 and
NHS site C withdrew from the trial in February 2016.
The trial initially opened to recruitment on 8th Decem-
ber 2015 at NHS sites A and B, with NHS sites D and E
opening to recruitment on 11th August 2016. The trial
was closed early on 23rd September 2016 because of
poor recruitment.
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Contracting
The main contract was between the funder (NIHR Health
Technology Assessment) and University 1, which was one
of the centres and also acted as sponsor. Subcontracts be-
tween University 1 and the participating centres and sites
concerning roles and responsibilities and the available
funding were a major issue. Initial subcontract templates
were drafted in November 2014 but could not proceed
further until the main contract and finances were agreed
with the funder in February 2015. Draft subcontracts were
sent to the relevant parties from University 1 contracts
department on 31st March 2015. The time taken to sign
contracts is shown in Table 1.
There were protracted discussions about the nature
and content of the subcontracts, as well as the division
of responsibilities between the academic partners and
the NHS sites. In the final adopted model, the subcon-
tracts were between the NHS sites and the sponsor, with
Fig. 2 Trial timetable. MHRA Medicine and Healthcare products Regulatory Agency, NHS National Health Service, R&D Research and Development,
REC Research ethics committee
Table 1 Time taken to sign subcontracts
University or NHS site Date subcontract signed Time to sign in days
NHS Site A 8th April 2015 9
University 2 7th July 2016 378
NHS Site B 20th October 2015 197
University 3 24th July 2015 115
NHS Site C 14th August 2015 131
University 4 2nd June 2016 427
NHS Site D 7th July 2016 459
NHS Site E 7th July 2016 459
University 5 Never signed > 550
NHS Site F Never signed > 550
NHS National Health Service
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universities providing academic support rather than tak-
ing on contractual responsibilities [36].
There were initial discussions about whether to have a
tripartite subcontract between University 1, University 4
and NHS site D, but after further discussion it was agreed
that University 1 would have separate subcontracts. In
addition, physiotherapy services were provided by two
NHS sites, and separate subcontracts were needed for each.
Two clinical rheumatology services were being merged
during the trial set-up. The Clinical Trials Unit at Univer-
sity 4 had recently had an MHRA inspection in autumn
2015, and the learning from that recent inspection led to
further discussions concerning sponsorship arrangements,
delegated duties and the wording of the contract to clarify
the role of the NHS sites, which resulted in further delay.
There were delays with the agreement between University
1, University 5 and NHS Site F regarding delineation of the
roles and responsibilities of the NHS site and University 5,
which included the costing model for the MRI. These dis-
cussions were still ongoing when the study was stopped.
The funder also requested oversight of all the subcon-
tracts before they were signed. Delays with the subcon-
tracts led to delays with recruitment and retention of
staff at the trial sites.
Excess treatment costs
In the United Kingdom, the costs of a pharmacological
treatment in an RCT are met by a participating pharma-
ceutical company or by the participating NHS organisa-
tion, and not by the research funder. These ETCs
amounted to more than £1000 per participant in the inter-
vention group. In Wales ETCs are managed centrally and
were agreed by the Welsh government for the two Welsh
sites (A and F), whereas in England individual NHS sites
are responsible. An ETC application was submitted to
NHS site B in June 2014 and approved on 11th March
2015. In NHS site D an initial application for ETCs was
declined owing to insufficient funds. The co-investigators
from University 4 led negotiations with both NHS site D
and the local Clinical Commissioning Groups (CCGs).
Both parties argued that they were not funded to support
these ETCs, despite guidance on attributing the costs of
health and social care research and development [37]. Fol-
lowing negotiation it was agreed that the costs would be
split between the local CCGs and the charitable funds
from NHS site D. ETCs were approved for NHS site D on
19th August 2015. Provisional ETCs were agreed for NHS
site C, who were told that it would be finalised once re-
search and development approval was given.
Withdrawal of site
Eight months after initiation, NHS site C reviewed the risk
assessment of the trial. The locality has a high incidence
of TB, and there had recently been several difficult and
complex cases treated locally, which had drawn the atten-
tion of the local press and community pressure groups
[38, 39]. Adalimumab is known to reactivate latent TB
[19], and all patients should be evaluated for TB before
commencing treatment. The principal investigator (PI)
was worried about the risk of reactivating TB with the ini-
tial 80-mg dose of adalimumab and decided to withdraw
from the trial. Consequently University 3 also withdrew
from the trial. This withdrawal led to a risk review for the
other sites, who concluded that available data indicated an
acceptable risk of infection in their populations, which
was consistent with advice provided in the patient
information sheet.
Research physiotherapist recruitment
Delays in signing subcontracts and setting up sites led to
delays in recruiting the research physiotherapists at study
sites. In NHS site A a physiotherapist was seconded from
the NHS physiotherapy department but was required to
return to clinical duties because of staffing shortages. This
led to delays in recruiting participants into the trial, and
to the loss of potential participants. The availability of re-
search nurses and consultant rheumatologists was limited
owing to other clinical commitments, so co-ordination of
biological agent counselling and investigations was diffi-
cult within the time available.
Trial recruitment
Recruitment data for the trial are presented in Fig. 3,
and reasons for withdrawal or exclusion are listed in
Table 2. NHS sites A and B recruited from December
2015 to September 2016. NHS sites D and E recruited
from August to September 2016.
Recruitment was less than anticipated. Invitation let-
ters were sent to 1546 potential participants across sites
A and B; 583 (38%) were interested in participating and
underwent pre-screening by telephone. At pre-screening
210 (36%) did not have sciatica according to our criteria,
and 173 (30%) had had symptoms for longer than 6
months, making them ineligible for the trial. Twenty five
(4.3%) attended for screening at the first clinic assess-
ment, 13 (52%) were eligible after the second clinical as-
sessment, and 8 were randomised. The other five were
eligible but could not be randomised, owing to study
closure.
In NHS site A, 16 GP practices identified eligible pa-
tients presenting to the practice using database searches
or opportunistic referral. Musculoskeletal clinics and
physiotherapy departments also searched for eligible pa-
tients presenting to their clinics.
NHS site B recruited mainly from a secondary care
back pain service rather than from primary care and had
a higher rate of exclusion because of longer duration of
symptoms (19% of those excluded) than in the other
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sites (NHS site A, 4%; NHS sites D and E, 5%). It
was noted by the PI at this site that referrals of pa-
tients with sciatica to the clinics had decreased be-
tween planning stages and the start of trial
recruitment, owing to a change in the referral path-
way commissioned by the local CCG. Therefore, the
planned recruitment pathway was changed to inviting
GP practices to identify eligible patients by database
search or opportunistic referral, independent of refer-
ral to specialist services. Database searches com-
menced at 12 practices in June 2016; 756 potential
participants were identified by GP practices, 11 were
invited to first clinical assessment screening, and 5
provided initial consent to participate before the trial
was terminated.
NHS sites D and E had opened to recruitment on
11th August 2016, but the trial was closed on 26th
September 2016. During this period there was a
reasonable response rate of 14 of 43 invitations to
participate, and nearly half of these, 6 of 14, were
made by GPs handing out trial information packs
during primary care consultations. This method of
recruitment could have been more successful, but we
were unable to test this properly before the trial
closed. One patient who was eligible after assessment
by the research physiotherapist was not able to
participate because of trial closure.
Adverse events
No adverse events or adverse reactions were recorded
for any of the eight participants.
Discussion
Summary of lessons learnt
This study has several important findings with major im-
plications for developing evidence, within a UK setting,
for challenging, expensive interventions with the potential
for rare but significant side effects. We found that treat-
ment pathways for acute sciatica varied across research
sites and changed during the study period. This necessi-
tated a flexible and heterogeneous approach to study
recruitment, matching local treatment pathways. It was
possible to introduce a novel treatment approach (biologic
therapy) requiring specialist services (rheumatology), not
normally a part of existing treatment pathways, within the
context of a clinical trial. However, delivering this RCT
was challenging, involving multiple professional groups
across different health care organisations. In the future,
additional feasibility studies, more efficient site set-up, im-
proved and pilot-tested recruitment methods and longer
recruitment periods might be appropriate.
There were four main factors that led to delays and
early trial closure: contracting issues, securing the
payment of ETCs, site withdrawal due to concerns about
reactivating TB in a highly prevalent area, and a complex
Fig. 3 Participant flow diagram for NHS sites A, B, D and E
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trial recruitment process that did not always match local
care pathways. There were long delays agreeing and ex-
changing subcontracts with participating centres and
sites, and contractual discussions with one site were
never concluded. Earlier agreement between sponsor,
university centres and NHS sites might have been facili-
tated by the use of model agreements such as the Bruns-
wick research collaboration agreement [40]; site
feasibility questionnaires; or research infrastructure that
could facilitate the contracting process in multi-site re-
search, such as the National Institute of Health Research
Translational Research Partnership [41].
Negotiations for the ETCs were protracted in England,
where responsibility for these costs had to be negotiated
with different NHS organisations with competing cost
pressures; new arrangements are needed [42]. One site
withdrew from the RCT before starting recruitment
because of a change in the PI’s perception of acceptable
risk in the local population, fuelled by recent high-profile
media cases. Further discussions between the trial
management group and the local PI around potential
risks, related concerns and the degree of equipoise might
have prevented site withdrawal.
During trial set-up new national management guid-
ance was published [6], as well as a new national back
pain and radicular pain pathway [7]. In one site the local
sciatica management pathway changed around the time
that it opened to recruitment. This site initially relied
only on referrals to its secondary care musculoskeletal
service but later involved the primary care research net-
work, which was starting to identify participants just be-
fore trial closure. In the other open site there were
operational issues with identifying the research physio-
therapist resource and fitting the trial around the clinical
commitments of participating clinicians.
The main method for identifying participants was
retrospective GP record review, but this had a low rate
of response, with only a small proportion seen at the
screening assessment. We had modelled the numbers of
eligible participants for our recruitment projections on
the previous Assessment and Treatment of Leg pain As-
sociated with the Spine (ATLAS) cohort study, which
identified patients in real time as they were consulting,
with retrospective record review used only as a backup
[43]. Although we identified large numbers of potential
participants, only small numbers returned reply slips in-
dicating a willingness to participate. It is not known why
potentially eligible participants did not wish to partici-
pate. Informal feedback suggested that some patients
might have been much improved by the time they were
contacted about the trial; some might have found the
trial procedures too burdensome, such as the complex
two-stage recruitment process; whilst others might not
have wished to participate in an RCT, especially in a
clinical trial of an investigational medicinal product in-
volving a medication with significant potential adverse
effects. Greater patient and public involvement could
Table 2 Reasons for withdrawal and exclusion for patients in
NHS sites A, B, D and E
Reasons for withdrawal and exclusion from invitation to
first clinical assessment
1520
Did not confirm interest 963
No sciatica 210
Symptoms persisting for longer than 6 months 173
Widespread pain throughout body 25
No response or no longer interested 23
No leg pain 20
Complicated symptoms 18
Previous lumbar spinal surgery 16
Trial closed early to recruitment 14
Previous surgery 11
Symptoms resolved/improved 10
Pain in both legs 7
Contraindications to MRI 6
Expressed interest but delay in telescreening due to
site staffing issues means no longer meet criteria for
inclusion (e.g. no longer in pain or have recently
breached the > 22-week exclusion window
since replying)
6
Serious spinal pathology 4
Unable to communicate in English or Welsh 3
Mental health problems 3
Current leg pain worse than or as bad as back pain 3
Previous episode of sciatica in the last 6 months 2
Incidental serious pathology identified by MRI 1
Previous use of biological agents targeting TNF-α 1
Contraindications to adalimumab 1
Pregnant or breastfeeding 1
Reasons for withdrawal and exclusion from first clinical
assessment to second clinical assessment
17
Mild symptoms – discharged to GP care 7
Study closure 5
Over time limit for second clinical assessment 1
TB screening failed 1
Participant revealed long term history of widespread
pain at screening – particularly in shoulders
1
No positive neurological test 1
Patient did not attend appointment and could not be
contacted
1
Reasons for withdrawal and exclusion from 6-week
follow-up to 6-month follow-up
4
Study closure 4
Abbreviations: GP General practitioner, MRI Magnetic resonance imaging, NHS
National Health Service, TB Tuberculosis, TNF Tumour necrosis factor
Williams et al. Trials  (2018) 19:408 Page 8 of 12
offer insights into how to explore this. Two of the clin-
ical sites were going to recruit participants using the
same methods as the ATLAS cohort, which have been
used successfully in another RCT of primary
care-delivered treatment for sciatica [44]. However, these
two sites signed their contracts just prior to trial closure.
Although potential participants had started to be identi-
fied, there was insufficient time to recruit them.
The current management of RCTs within the United
Kingdom has emphasised recruitment efficiency and de-
livery of outcomes within short timelines [45]. This re-
mains appropriate for treatments that fit within existing
treatment pathways; when they do not, a new pathway
must be developed specifically for the trial. In the
current study we introduced medical screening and bio-
logic therapy administration delivered through experi-
enced secondary care rheumatology services. The
heterogeneity of existing clinical pathways for sciatica
(in primary and in secondary care) necessitated a multi-
faceted approach, with different solutions for different
sites, requiring flexibility when pathways at single sites
changed between the planning and execution of the trial.
Comparison with previous literature
The previous systematic review of biological agents for
sciatica found a small number of RCTs and other studies
with small numbers recruited [17]. Many of these studies
also had poor rates of recruitment, both in the UK NHS
[46] and elsewhere in Europe [47].
Slow or inadequate recruitment to publicly funded mul-
ticentre RCTs is still a common problem [48]. Systematic
reviews of RCTs that compared methods to increase trial
recruitment found that effective interventions included
telephone or text reminders 2 weeks after receiving the let-
ter of invitation, the use of lay advocates who were already
involved in the study, monetary incentives, and
non-blinding of trial participants. The evaluation of re-
cruitment strategies within RCTs was advocated [49, 50].
Results of a systematic review concerning the recruitment
activity of clinicians in RCTs include the use of qualitative
research to identify and overcome recruitment barriers, re-
duction of clinical workload associated with participation
in RCTs, extra training and protected research time [51].
Implications for future research
We make a number of recommendations for future re-
searchers (Table 3). A number of these are pertinent to all
RCTs conducted in the United Kingdom. For example, we
would recommend full discussions between the sponsor’s
contracting department and all university centres and
NHS sites to obtain early agreement about what the con-
tracts need to include and how the contracting process
should be arranged, so that the university centres and the
NHS sites have a clear understanding of their delegated
roles and tasks. This may involve model contracts such as
the Brunswick research collaboration agreements, which
have been designed to be suitable for the majority of cases
where two or more universities receive a joint research
grant [40]. Early discussions about site requirements, per-
haps using a site feasibility questionnaire, early dialogue
with sites’ research and development departments, and
the early appointment of research staff in each site would
facilitate trial set-up.
We also make recommendations pertinent to the cir-
cumstances of this particular RCT. The impact of re-
search staff shortages, in this case a research
physiotherapist at one site, could be avoided by having
dedicated research staff. In addition, involvement of the
research staff during the initial planning stage would
have been useful for planning the recruitment strategy.
Further qualitative research is needed to identify rea-
sons for low recruitment rates, using methods such as
the QuinteT Recruitment Intervention, which uses a
combination of standard and innovative qualitative re-
search methods, with some simple quantification, to
understand recruitment and identify sources of difficulty
[52]. Possible reasons for poor recruitment include con-
cerns about the nature of the trial intervention and its
side effects, perceived burden of trial participation, nat-
ural history of recovery of severe sciatica, perceptions
about the nature of sciatica itself, and whether the treat-
ment under study is consistent with these. People who
believe that their sciatica will resolve quickly (either
spontaneously or with treatment) are unlikely to commit
to a trial of medical intervention with long follow-up,
Table 3 Ten lessons learnt for consideration in a future trial
Contracts 1 Early agreement between sponsor, NHS sites and
university centres about how the contracting
process should be arranged with model research
collaboration agreements
Site set-up 2 Early discussions about site requirements using
a site feasibility questionnaire
3 Recruitment of a dedicated research
physiotherapist (or other personnel) at each site
Treatment
acceptability
4 Establish if the proposed treatment is acceptable
to all principal investigators
5 Determine if the proposed treatment is
acceptable to sciatica patients, using further
qualitative research
Recruitment 6 Simplify two-stage recruitment process
7 Use telephone or text reminders two weeks
after patients receive letter of invitation
8 Use of lay advocates already recruited into
the study
9 Recruitment during real-time GP consultations
Feasibility study 10 Feasibility study testing several key recruitment
methods
GP General practitioner, NHS National Health Service
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particularly if they perceive that it would not provide
(and might delay) definitive treatment. Such beliefs in
the study population might not be well-founded in evi-
dence, and pre-recruitment education might be neces-
sary to help potential participants appreciate the
possible benefits that might be achieved from novel in-
terventions that are being investigated.
Patient recruitment from ‘real-time’ GP consultations
may have reduced the delays associated with retrospect-
ive checks of GP consultations and from referrals to
physiotherapy and secondary care settings. Unfortu-
nately, because of delays in agreeing ETCs and finalising
contracts, there was insufficient time to recruit any par-
ticipants using this method before trial closure.
Conclusions
A trial of biological therapy in patients with sciatica still
needs to be performed, but it would require a clearer
contracting process, qualitative research to ensure that
patients (and clinicians) would be willing to participate,
and more efficient recruitment methods, with the least
possible burden on patients.
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